INTERVENTIONALCOMPLETEDNCT01025700
A Double-Blind Placebo Control Study on the Use of Nabilone for Outpatient Management of Acute Marijuana Withdrawal
Safety of Nabilone in reducing marijuana craving
Locally preserved from ClinicalTrials.govOpen ClinicalTrials.gov↗last source update 2011-02-17
What this record can show
Protocol only - no registry results posted
This locally preserved record separates the registered protocol from source-reported registry results. Neither is a treatment recommendation.
Registry facts
Study at a glance
- Phase
- PHASE2, PHASE3
- Enrollment
- 35 (ESTIMATED)
- Start date
- 2009-06
- Sponsor
- University of British Columbia
- Design
- RANDOMIZED · PARALLEL · TREATMENT
- Locations
- 1
- Results record
- Not present in registry snapshot
Randomized double blind trial into the safety and efficacy of Cesemat for the treatment of marijuana use
Marijuana SmokingEfficacyMarijuanaReductionCraving
Linked local records
Related local records
Local links use governed condition terms or exact source-reported intervention names. They are navigation candidates, not efficacy claims.
Conditions
No published condition report matched.
Cannabinoids and active compounds
No governed compound link was found.
Medicines
No exact medicine-name link was found.
Interventions
What was registered
DRUGCesemat
1 mg capsule per day for 21 days
Nabilone Eligibility
Population and criteria
- Sex
- ALL
- Minimum age
- 19 Years
- Maximum age
- 65 Years
- Healthy volunteers
- Not accepted
Inclusion criteria
- 19 years or older
- History of marijuana use
primary outcomes
primary measures
Safety and tolerability to Nabilone
secondary outcomes
secondary measures
Marijuana craving questionnaire
Publications
Locally readable linked articles
No exact PMID-linked public article is currently readable locally.
Snapshot provenance
- Snapshot
- 17b9a83d-892c-4741-96ad-d69548147993
- Retrieved
- 11/09/2026, 14:54:54
- SHA-256
- 8707c331075306c15e04feb97ad3885d28e7b9aa6b543510057d69e3c2c49f88